Kevin Hrusovsky

Microfluidics applications are rising in both scientific and clinical medicine and Kevin Hrusovsky, CEO of chip-maker Caliper Life Sciences (Hopkinton, MA) expects to see 10 to 15% growth this year alone.  Recently, Agilent Technologies (Germantown, MD) renewed for seven years its exclusive agreement with Caliper for microfludic chips.  Hrusovsky believes “. . . our microfluidics technologies will continue growing as a critical tool for sample analysis as well as for sample preparation, particularly as sequencing and gene-expression workflows become fundamental to the realization of personalized medicine.”  Actually, that could be a forecast for the industry at large.          MORE

Image Credit:  Caliper Life Sciences